ArticleJournal of gastrointestinal oncology2022
Cost-effectiveness of screening with polymerase chain reaction for
Article in Journal of gastrointestinal oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Economic Evaluation of Gastric Cancer Screening Strategies: A Systematic Review.Journal of gastrointestinal cancer · 2025Pooled it
- Cost-effectiveness of a real-time screening strategy for bacterial vaginosis using qPCR to prevent preterm birth: results from a randomized prospective multicenter study.Cost effectiveness and resource allocation : C/E · 2026Article
- Review
- Review
- Evolving Concepts in Helicobacter pylori Management.Gastroenterology · 2024Review
- Health economic evaluation on population-basedChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Cost-effectiveness of screening with polymerase chain reaction forJournal of gastrointestinal oncology · 2022Article
- Optimizing Benefits-Harms of H. pylori Screen-and-Treat Programs Tailored to the Regional Settings.HelicobacterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Background: Methods: A Markov cohort state-transition model was developed to compare three strategies: no screening with opportunistic eradication, Results: PCR screening was cost-effective and had an incremental-cost effectiveness ratio per quality adjusted life-year (QALY) of $38,591.89 when compared to Conclusions: Our modeling study finds PCR screening and treating of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.